DIA: Marks rejects ‘cookie cutter’ approach to rare disease reviews
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesClinical TrialsNorth AmericaPharmaceuticalsProduct LifecycleRegulatory NewsJoanne S. EglovitchBiologics/ biosimilars/ vaccinesClinical TrialsNorth AmericaPharmaceuticalsProduct Lifecycle